Loading...
XNAS
CLGN
Market cap29mUSD
Jun 03, Last price  
2.54USD
1D
11.40%
1Q
-16.72%
Name

Collplant Biotechnologies Ltd

Chart & Performance

D1W1MN
P/E
P/S
56.49
EPS
Div Yield, %
Shrs. gr., 5y
18.10%
Rev. gr., 5y
-25.98%
Revenues
515k
-95.30%
000075,911479,9174,788,3802,318,0006,137,00015,641,000299,00010,959,000515,000
Net income
-17m
L+136.63%
-4,601,601-4,749,682-3,342,401-4,786,346-7,239,669-6,051,000-6,249,000-14,697,000-5,808,000409,000-16,753,000-7,019,000-16,609,000
CFO
-14m
L+410.06%
0000000-5,703,000-4,451,0002,501,000-13,698,000-2,763,000-14,093,000
Earnings
Jun 04, 2025

Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
IPO date
Sep 01, 1993
Employees
73
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
515
-95.30%
10,959
3,565.22%
299
-98.09%
Cost of revenue
12,140
12,475
10,655
Unusual Expense (Income)
NOPBT
(11,625)
(1,516)
(10,356)
NOPBT Margin
Operating Taxes
(172)
Tax Rate
NOPAT
(11,625)
(1,516)
(10,184)
Net income
(16,609)
136.63%
(7,019)
-58.10%
(16,753)
-4,196.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,108
1,874
BB yield
-1.52%
-2.03%
Debt
Debt current
806
624
529
Long-term debt
5,356
5,694
5,293
Deferred revenue
Other long-term liabilities
Net debt
(5,747)
(20,356)
(24,019)
Cash flow
Cash from operating activities
(14,093)
(2,763)
(13,698)
CAPEX
(483)
(954)
(1,316)
Cash from investing activities
(539)
(1,156)
28,922
Cash from financing activities
9
1,108
1,874
FCF
(11,047)
(1,698)
(10,180)
Balance
Cash
11,909
26,674
29,653
Long term investments
188
Excess cash
11,883
26,126
29,826
Stockholders' equity
(109,336)
(92,728)
(85,818)
Invested Capital
125,882
124,227
121,010
ROIC
ROCE
EV
Common stock shares outstanding
11,455
11,389
11,033
Price
3.60
-43.66%
6.39
-23.47%
8.35
-48.96%
Market cap
41,236
-43.34%
72,777
-21.00%
92,128
-52.94%
EV
35,489
52,421
68,109
EBITDA
(10,587)
(414)
(9,280)
EV/EBITDA
Interest
17
10
172
Interest/NOPBT